Association of bupropion and naltrexone for the treatment of obesity
Abstract
Introduction: The obesity, a global challenge, many times demands multiple approaches, besides the change of the lifestyle, as the pharmacotherapy. The bupropion (BUP) and naltrexone (NAL) association stands out on weight loss, exploring its psychoneuroendocrine effects. The objective of this revision was to verify the psychoneuroendocrine role of the association of BUP and NAL on weight loss in obesity. Materials and methods: The study used electronic databases, covering works published in the period of 2008 to 2023, directly related with the use of BUP and NAL in the obesity treatment. Discussion and results: The BUP, used on depression treatment through inhibition of the dopamine and noradrenaline reuptake, activates the POMC in hypothalamus, reducing the appetite. The NAL, used on opiates addiction as MOP-R antagonist, associated with BUP, effectively reduces the subjective pleasantness of food, especially the palatable ones, through interaction with the mesolimbic reward system. Studies indicate the efficiency of BUP-NAL in the reduction of corporal weight. However, due to cardiovascular uncertainty, this combination isn’t the first choice for weight control. Conclusion: So it’s possible to conclude that the BUP-NAL combination is efficient for weight loss, when it’s associated with the conservative treatment. However, the cardiovascular safety and the collateral effects deserves attention, as these challenges the search for more personalized approaches.
References
-Albuquerque, M.P. Efeitos do tratamento com a associação naltrexona/bupropiona em rins de ratos obesos: uma análise histopatológica, morfométrica e estereológica. Dissertação de Mestrado em Patologia. Universidade Federal de Pernambuco. Recife. 2020.
-Barrea, L.; Pugliese, G.; Muscogiuri, G.; Laudisio, D.; Colao, A. Savastano, S. New-generation anti-obesity drugs: naltrexone/bupropion and liraglutide. An update for endocrinologists and nutritionists. Minerva endocrinológica. Vol. 45. Num. 2. 2020. p. 127-137.
-Bello, N.T. Update on drug safety evaluation of naltrexone/bupropion for the treatment of obesity, Expert Opnion on Drug Safety. Vol. 18. Num. 7. 2019. p. 549-552.
-BVS. Biblioteca Virtual em Saúde. “Todos precisam agir”: 04/3 - Dia Mundial da Obesidade. Disponível em: https://bvsms.saude.gov.br/todos-precisam-agir-04-3-dia-mundial-da-obesidade/. Acesso em: 15/11/2023.
-Brauer, P.; Gorber, S.C.; Shaw, E.; Singh, H.; Bell, N.; Shane, A.R.E.; Jaramillo, A.; Tonelli, M; Canadian Task Force on Preventive Health Care. Recommendations for prevention of weight gain and use of behavioral and pharmacologic interventions to manage overweight and obesity in adults in primary care. Cmaj. Vol. 187. Num. 3. 2015. p. 184-195.
-Chakhtoura, M.; Haber, R.; Ghezzawi, M.; Rhayem, C.; Tcheroyan, R.; Mantzorosc, C.S. Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. e Clinical Medicine. Num. 58: 2023. p. 101882.
-Contrave (cloridrato de naltrexona + cloridrato de bupropiona). Alexandre Canellas de Souza. Rio de Janeiro: Merck S.A., 2021. Bula do medicamento.
-Davis, C.J.C. Compulsive overeating as an addiction disorder. A review of theory and evidence. Appetite. Vol. 53. Num. 1. 2009. p. 1-8.
-Davis, C.A.; Levitan, R.D.; Reid, C.; Carter, J.C.; Kaplan, A.S.; Patte, K.A. King, N.; Curtis, C.; Kennedy, J.L. Dopamine for “wanting” and opioids for “liking”: a comparison of obese adults with and without binge eating. Obesity. Vol. 17. Num. 6. 2009. p. 1220-1225.
-Dubern, B. Mutações MC4R e MC3R. The ECOG’s eBook on Child and Adolescent Obesity. 2015.
-Fernandes, R.C. Efeitos do tratamento com a associação naltrexona/bupropiona em fígados de ratos obesos: aspectos histomorfométricos. Dissertação de Mestrado em Patologia. Universidade Federal de Pernambuco. Recife. 2019.
-FDA. Food and Drug Administration. FDA approves weight-management drug Contrave. 2014. Disponível em: https://wayback.archive-it.org/7993/20170112222826/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm413896.htm. Acesso em: 15/11/2023.
-Gafoor, R.; Booth, H.P.; Gulliford, M.C. Antidepressant utilization and incidence of weight gain during 10 years’ follow-up: population-based cohort study. BMJ. Vol. 361. 2018.
-Gasques, L.S.; Abrão, R.M.; Diegues, M.E. M.; Gonçalves, T.S.A. Obesidade genética não sindrômica: histórico, fisiopatologia e principais genes. Arquivos de Ciências da Saúde da UNIPAR, Umuarama. Vol. 26. Num. 2. 2022. p. 159-174.
-Greenway, F.L.; Dunayevich, E.; Tollefson, G.; Erickson, J.; Guttadauria, M.; Fujioka, K.; Cowley, M.A. NB-201 Study Group. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. The Journal of clinical endocrinology and metabolismo. Vol. 94. Num. 12. 2009a. p. 4898-4906.
-Greenway, F.L.; Fujioka, K.; Plodkowski, R.A.; Mudaliar, S.; Guttadauria, M.; Erickson, J.; Kim, D.D.; Dunayevich, E. COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. Vol. 376. Num. 9741. 2010. p. 595-605. doi:10.1016/S0140-6736(10)60888-4
-Greenway, F.L.; Whitehouse, M.J.; Guttadauria, M.; Anderson, J.W.; Atkinson, R.L.; Fujioka, K.; Gadde, K.M.; Gupta, A.K.; O’neil, P.; Schumacher, D.; Smith, D.; Dunayevich, E.; Tollefson, G.; Weber, E.; Cowley, M.A. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). Vol. 17. Num. 1. 2009b. p. 30-39. doi:10.1038/oby.2008.461
-Grilo, C.M.; Lydecker, J.A.; Morgan, P.T.; Gueorguieva, R. Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study. Clinical Therapeutics. Vol. 43. Num. 1. 2021. p. 112-122.e1. doi:10.1016/j.clinthera.2020.10.010
-Guerdjikova, A.I.; Mori, N.; Casuto, L.; McElroy, S.L.; Binge Eating Disorder. Psychiatric Clinical of North America. Vol. 40. Num. 2. 2017. p. 255-266. doi:10.1016/j.psc.2017.01.003
-Hollander, P.; Gupta, A.K.; Plodkowski, R.; Greenway, F.; Bays, H.; Burns, Colleen, B.; Klassen, P.; Fujioka, K.; COR-Diabetes Study Group. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes care. Vol. 36. Num. 12. 2013. p. 4022-4029.
-Jantaratnotai, N.; Mosikanon, K.; Lee, Y.; McIntyre, R.S. The interface of depression and obesity. Obesity research & clinical practice. Vol. 11. Num. 1. 2017. p. 1-10. doi: 10.1016/j.orcp.2016.07.003
-Karatsoreos, I.N.; Thaler, J.P.; Borgland, S.L.; Champagne, F.A.; Hurd, Y.L.; Hill, M.N. Food for thought: hormonal, experiential, and neural influences on feeding and obesity. Journal of Neuroscience. Vol. 33. Num. 45. 2013. p. 17610-6.
-Landeiro, F.M.; Quarantini, L.C. Obesidade: Controle Neural e Hormonal do Comportamento Alimentar. Revista De Ciências Médicas e Biológicas. Vol. 10. Num. 3. 2010. p. 236-245.
-Lee, M.W.; Fujioka, K. Naltrexone for the treatment of obesity: review and update. Expert Opin Pharmacother. Vol. 10. Num. 11. 2009. p. 1841-1845.
-Leite, L.D.; Rocha, E.D.M.; Neto, J.B. Obesidade: uma doença inflamatória. Revista Ciência & Saúde. Vol. 2. Num. 2. 2009. p. 85-95.
-Luppino, F.S.; Wit, L.M.; Bouvy, P.F.; Stijnen, T.; Cuijpers, P.; Penninx, B.W.J.H.; Zitman, F.G. Overweight, obesity, and depression: a systematic review and meta-analysis of longitudinal studies. Archives of general psychiatry. Vol. 67. Num. 3. 2010. p. 220-229. doi: 10.1001/archgenpsychiatry.2010.2
-Maior, A.S. Regulação hormonal da ingestão alimentar: um breve relato. Medicina. Vol. 45. Num. 3. 2012. p. 303-309.
-McElroy, S.L.; Guerdjikova, A.I.; Kim, D.D.; Burns, C.; HarrisCollazo, R.; Landbloom, R.; Dunayevich, E.; Naltrexone/Bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study. The primary care companion for CNS disorders. Vol. 15. Num. 3. 2013. p. 25594. doi: 10.4088/PCC.12m01494
-McIntyre, R.S.; Paron, E.; Burrows, M.; Blavignac, J.; Gould, E.; Camacho, F.; Barakat, M. Psychiatric Safety and Weight Loss Efficacy of Naltrexone/bupropion as Add-on to Antidepressant Therapy in Patients with Obesity or Overweight. Journal of Affective Disorders. Vol. 289. 2021. p. 167-176. doi:10.1016/j.jad.2021.04.017
-Moyer, V.A.; US Preventive Services Task Force. Screening for and management of obesity in adults: US Preventive Services Task Force recommendation statement. Annals of internal medicine. Vol. 157. Num. 5. 2012. p. 373-378. doi: 10.7326/0003-4819-157-5-201209040-00475
-Niessen, S.E.; Wolski, K.E.; Prcela, L.; Wadden, T.; Buse, J.B.; Bakris, G.; Perez, A.; Smith, S.R. Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. JAMA. Vol. 315. Num. 10. 2016. p. 990-1004. doi:10.1001/jama.2016.1558
-OPAS. Organização Pan-Americana da Saúde. Dia Mundial da Obesidade 2022: acelerar ação para acabar com a obesidade. Disponível em: https://www.paho.org/pt/noticias/4-3-2022-dia-mundial-da-obesidade-2022-acelerar-acao-para-acabar-com-obesidade. Acesso em: 15/11/2023.
-Pedwal, R. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Current Opinion in Investigational Drugs. Num. 10. 2009. p. 1117-1125.
-Perreault, L. Obesity in adults: Drug therapy. UpToDate. 2023.
-Pi-sunyer, X.; Apovian, C.M.; Mcelroy, S.L.; Dunayevich, E.; Acevedo, L.M.; Greenway, F.L. Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis. International Journal of Obesity. Vol. 43. Num. 10. 2019. p. 2085-2094. doi: 10.1038/s41366-018-0302-z
-Pratt, L.A.; Brody, D.J. Depression and obesity in the US adult household population. US National Library of Medicine National Institutes of Health. p. 1-8. 2014.
-Ribeiro, G.; Santos, O.; Sampaio, D.; Obesidade: um fenótipo de dependência? Portuguesa de Endocrinologia, Diabetes e Metabolismo. Vol. 10. Num. 2. 2015. p. 193–199.
-Salari, N.; Jafari, S.; Darvishi, N.; Valipour, E.; Mohammadi, M.; Mansouri, K.; Shohaimi, S. Retraction Note: The best drug supplement for obesity treatment: a systematic review and network meta-analysis. Diabetology & Metabolic Syndrome. Vol. 15. Num. 1. 2023. p. 74-82. doi: 10.1186/s13098-023-01048-3
-Sande-Lee, S.V.; Velloso, L.A. Disfunção hipotalâmica na obesidade. Arquivo Brasileiro de Endocrinologia e Metabolismo. Vol. 56. Num. 6. 2012.
-Santos, A.F.S.; Souza, C.S.V.; Oliveira, L.S.; Freitas, M.F.L. Influência da dopamina e seus receptores na gênese da obesidade: revisão sistemática. Revista Neurociência. Vol. 22. Num. 3. 2014. p. 373-380.
-Santos, M.E.S.; Peixoto, J.L.B. Brazilian Journal of Development. Vol. 7. Num. 11. 2021. p. 106388-106398.
-Schutz, D.D.; Busetto, L.; Dicker, D.; Farpour-Lambert, N.; Pryke, R.; Toplak, H.; Widmer, D.; Yumuk, V.; Schutz, Y. European Practical and Patient-Centred Guidelines for Adult Obesity Management in Primary Care. Obesity Facts. Vol. 12. Num. 1. 2019. p. 40-66. doi: 10.1159/000496183
-Sharfstein, J.M.; Psaty, B.M. Evaluation of the Cardiovascular Risk of Naltrexone-Bupropion: A Study Interrupted. JAMA. Vol. 315. Num. 10. 2016, p. 984-986. doi:10.1001/jama.2016.1461
-Silva, G.R. Efeitos da associação naltrexona/bupropiona sobre a via dopaminérgica do comportamento alimentar em ratos wistar obesos. Dissertação de Mestrado em Neuropsiquiatria e Ciências do Comportamento. Universidade Federal de Pernambuco. Recife. 2018.
-Simpson, K.A.; Martin, N.M.; Bloom, S.R. Hypothalamic regulation of food intake and clinical therapeutic applications. Arquivos Brasileiros De Endocrinologia & Metabologia. Vol. 53. Num. 2. 2009. p. 120-128.
-Stefanakis, K.; Kokkinos, A.; Argyrakopoulou, G.; Konstantinidou, S.K.; Simati, S.; Kouvari, M.; Kumar, A.; Kalra, B.; Kumar, M.; Bontozoglou, N.; Kyriakopoulou, K.; Mantzoros, C.S. Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long interventional study. Diabetes, Obesity and Metabolism. Vol. 25. Num. 9. 2023. p. 2561-2574. doi: 10.1111/dom.15141
-Von Deneen, K.M.; Liu, Y. Obesity as an addiction: Why do the obese eat more? Maturitas. Vol. 68. Num. 4. 2011. p. 342-345.
-Wanderley, E.N.; Ferreira, V.A. Obesidade: uma perspectiva atual. Revista Ciência & Saúde Coletiva. Vol. 15. Num. 1. 2010. p. 185-194.
-Woo, Y.S.; Seo, H.; McIntyre, R.S.; Bahk, W. Obesity and its potential effects on antidepressant treatment outcomes in patients with depressive disorders: a literature review. International Journal of Molecular Sciences. Vol. 17. Num. 1. 2016. p. 80. doi: 10.3390/ijms17010080
Copyright (c) 2025 Bianca Ayumi Ogura, Nayandra Malta Mascarenhas, Lia Aguiar da Silva, Maria Clara Semprebom Rampazzo, Ellen Cristina Perek, Geórgia Fernandes de Almeida, Luciano Seraphim Gasques
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish in this journal agree to the following terms:
- Authors retain the copyright and grant the journal the right of first publication, with work simultaneously licensed under the Creative Commons Attribution License BY-NC which allows the sharing of the work with acknowledgment of the authorship of the work and initial publication in this journal.
- Authors are authorized to enter into additional contracts separately for non-exclusive distribution of the version of the work published in this journal (eg, publishing in institutional repository or book chapter), with acknowledgment of authorship and initial publication in this journal.
- Authors are allowed and encouraged to post and distribute their work online (eg, in institutional repositories or on their personal page) at any point before or during the editorial process, as this can bring about productive change as well as increase impact and impact. citation of published work (See The Effect of Free Access).
